Steel Grove Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Steel Grove Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,817	Closed	-$467K	–	272
2018 Q4	$467K	Hold	2,817	–	–	0.07%	205
2018 Q3	$543K	Sell	2,817 -51	-2%	-$9.08K	0.08%	196
2018 Q2	$487K	Hold	2,868	–	–	0.08%	196
2018 Q1	$467K	Buy	+2,868	New	+$468K	0.07%	218

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Steel Grove Capital Advisors's VRTX Position: Q1 2019 in Review

Steel Grove Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2019, closing a stake of 2,817 shares — an estimated $467K sold.

Steel Grove Capital Advisors first reported a position in VRTX in Q1 2018 and held it in 4 quarters. The position peaked at $543K in Q3 2018. 737 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

Steel Grove Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Steel Grove Capital Advisors sold 2,817 Vertex Pharmaceuticals shares in Q1 2019, an estimated $467K.
Steel Grove Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 4 quarters.
Steel Grove Capital Advisors's Vertex Pharmaceuticals position peaked at $543K in Q3 2018.
737 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on Steel Grove Capital Advisors's 13F filing for Q1 2019, filed 14 May 2019.